Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia
Cannabix is developing alcohol and marijuana breathalyzer devices to give law enforcement and employers a tool to enhance public safety
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of alcohol and marijuana breathalyzer screening devices for law enforcement and the workplace reports that it has commenced discussions with Breathalyser Sales & Service Pty Ltd. of Sydney, Australia (“Breathalyser SSP”) for the sales distribution of the Company’s Breath Logix Alcohol screening device (see Figure 1). Breathalyser SSP is a leading distributor of alcohol and drug testing devices for employers and personal use, offering well established alcohol product lines like Draeger and AlcoMeasure for the Australian market with regional offices in Perth, Melbourne and Brisbane. Breathalyser SSP has clients in a range of sectors including mining, oil and gas, industrial, trucking, warehousing and technology. Cannabix will be shipping its Breath Logix Industrial Series device to Breathalyser SSP for evaluation, preliminary marketing and business development purposes.
Ben Smit, Managing Director of Breathalyser Sales & Service Pty Ltd., stated, “We have been impressed with the Cannabix team’s ability to develop the Breath Logix wall mounted device over the last several months. Breathalyser Sales and Service is Australia’s oldest distributor and leader in the supply, service & calibration of drug and alcohol testing equipment. We see the Breath Logix Industrial Series fitting into the Australian marketplace well due to is rugged exterior, ease of use and unique cartridge technology. Autonomous employee alcohol screening is a major segment of our business and we welcome innovative products like the Breath Logix device.”
Figure 1. Breath Logix Industrial Series device
Breath Logix Industrial Series Features
The Breath Logix Industrial Series is a weather resistant device with a host of requested features including patent pending pre-calibrated cartridge technology which will allow site safety administrators to easily maintain their devices, and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance. This device can be used for pre-access alcohol testing, random testing, start-of-shift testing, pre-employment testing, return-to-work testing and post-incident testing. The device is currently being piloted as a solution for the 24/7 sobriety program which exists in several states.
The Breath Logix Alcohol device automatically checks the sobriety of a user and can take a picture to confirm and record identity while a breath sample is being delivered. Upon detection of positive breath alcohol result, the device will deliver a precise Blood Alcohol Content (BAC) level on the screen, and send a real-time alert via text message, e-mail and to a dedicated web portal. Furthermore, the system logs user BAC for incident reporting and historical investigations. The Breath Logix helps organizations save money by deploying an autonomous alcohol screening device which eliminates the need for dedicated alcohol screening administrators using conventional handheld devices. There is no assurance that evaluators of the Company’s breathalyzer technology will come to terms on distribution or enter into a sales agreement with the Company.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of Breath Logix Series of autonomous breath alcohol detection devices for employers and a range of other settings.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of breathalyzer technology will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. There is no assurance that evaluators of the Company’s breathalyzer technology will agree or come to terms on distribution or enter into a sales agreement, of any kind. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9a70ac03-45e6-454a-bd18-ff1e61e6ff60.
